

1 **Genomic Locus Modulating IOP in the BXD RI Mouse Strains**

2
3 Rebecca King¹, Ying Li¹, Jiaying Wang^{1,2}, Felix L. Struebing¹ and Eldon E. Geisert¹

4
5
6 ¹Department of Ophthalmology, Emory University 1365B Clifton Road NE Atlanta GA,
7 30322

8
9 ²Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin,
10 China

11
12
13
14
15
16 Corresponding Author:

Eldon E. Geisert
Professor of Ophthalmology
Emory University
1365B Clifton Road NE
Atlanta GA 30322
email: egeiser@emory.edu
Phone: 404-778-4239

25 **Abstract**

26

27 Purpose: Intraocular pressure (IOP) is the primary risk factor for developing glaucoma.
28 The present study examines genomic contribution to the normal regulation of IOP in the
29 mouse.

30

31 Methods: The BXD recombinant inbred (RI) strain set was used to identify genomic loci
32 modulating IOP. We measured the IOP from 532 eyes from 33 different strains. The IOP
33 data will be subjected to conventional quantitative trait analysis using simple and
34 composite interval mapping along with epistatic interactions to define genomic loci
35 modulating normal IOP.

36

37 Results: The analysis defined one significant quantitative trait locus (QTL) on Chr.8 (100
38 to 106 Mb). The significant locus was further examined to define candidate genes that
39 modulate normal IOP. There are only two good candidate genes within the 6 Mb over the
40 peak, *Cdh8* (Cadherin 8) and *Cdh11* (Cadherin 11). Expression analysis on gene
41 expression and immunohistochemistry indicate that *Cdh11* is the best candidate for
42 modulating the normal levels of IOP.

43

44 Conclusions: We have examined the genomic regulation of IOP in the BXD RI strain set
45 and found one significant QTL on Chr. 8. Within this QTL that are two potential
46 candidates for modulating IOP with the most likely gene being *Cdh11*.

47

48

49 **Introduction**

50 Glaucoma is a diverse set of diseases with heterogeneous phenotypic presentations
51 associated with different risk factors. Untreated, glaucoma leads to permanent damage of
52 axons in the optic nerve and visual field loss. Millions of people worldwide are affected
53 [1, 2] and it is the second leading cause of blindness in the United States [3]. Adult-onset
54 glaucoma is a complex collection of diseases with multiple risk factors and genes with
55 differing magnitudes of effects on the eventual loss of RGCs. The severity of the disease
56 appears to be dependent on the interaction of multiple genes, age, and environmental
57 factors [4]. There are also a number of phenotypic risk factors for POAG including: age,
58 ethnicity, central corneal thickness and axial length[5]. The primary risk factor is an
59 elevated intraocular pressure (IOP) [6]. There are known genetic mutations that affect
60 IOP that result in inherited glaucoma [7, 8]. The prime example is MYOC, a protein
61 secreted by the trabecular meshwork and mutations in this protein cause ER stress which
62 results in a decrease in the function of the trabecular meshwork and an elevation in IOP
63 [9, 10]. We know a considerable amount about the regulation of IOP from the production
64 of aqueous humor to the outflow pathways. IOP is a complex trait affected by different
65 tissues in the eye each of which is regulated by multiple genomic loci. Interestingly,
66 there are very few studies that have identified genomic loci modulating normal IOP.

67

68 In the present study, we are using the BXD RI strain set that is particularly suited for the
69 study of genetics and the effects on the severity of glaucoma. This genetic reference
70 panel presently consists of 80 strains [11], and we are now in the unique position of being
71 able to study the eyes of more than 80 strains with shuffled genomes from the two
72 parental strains, C57BL/6J and the DBA/2J. There are over 7,000 break points in our
73 current set of BXD strains. For this study, our group has measured IOP of 532 eyes from
74 33 strains to identify genomic loci modulating IOP. A systems genetics approach to
75 glaucoma is a relatively new branch of quantitative genetics that has the goal of
76 understanding networks of interactions across multiple levels that link DNA variation to
77 phenotype [12]. Systems genetics involves an analysis of sets of causal interactions
78 among classic traits such as IOP, networks of gene variants, and developmental,
79 environmental, and epigenetic factors. The main challenge is the need for comparatively

80 large sample size and the use of more advanced statistical and computational methods
81 and models. We finally have a sufficiently large number of strains to use this approach
82 [13, 14]. Our goal is now to combine data across several levels from DNA to ocular
83 phenotype and analyze them with newly developed computational methods to understand
84 pre-disease susceptibility to glaucoma along with the genetic networks modulating the
85 response of the eye to elevated IOP.

86

87

88 **Methods**

89 Mice: This study measured the IOP in the 33 BXD strains of mice along with the parental
90 strains the C57BL/6J mouse strain and the DBA/2J mouse strain. None of the BXD
91 strains included in this study carried both mutations (*Tyrrp1* and *Gpnmb*) known to cause
92 the severe glaucoma phenotype observed in the DBA2/J strain. All of the mice in this
93 study were between 60 and 120 days of age, a time before there is any significant
94 elevation in IOP due pigment dispersion [15]. The data presented in this paper is based on
95 measurements from 532 eyes with roughly equal numbers of male and female mice. All
96 breeding stock was ordered from Jackson Laboratories (Bar Harbor, ME) and maintained
97 at Emory. Mice were housed in the animal facility at Emory University, maintained on a
98 12 hr light/dark cycle (lights on at 0700), and provided with food and water ad libitum.
99 IOP measurement were made between 0900 and 1100. Both eyes were measured and the
100 data from each eye was entered into the database. An induction–impact tonometer
101 (Tonolab Colonial Medical Supply) was used to measure the IOP according to
102 manufacturer’s instructions and as previously described (Saleh M, Nagaraju M, Porciatti
103 2007; Nagaraju M, Saleh M, Porciatti V 2009). Mice were anesthetized with Avertin (334
104 mg/kg) or ketamine/xylazine (100,15mg/kg). Three consecutive IOP readings for each
105 eye were averaged. IOP readings obtained with Tonolab have been shown to be accurate
106 and reproducible in various mouse strains, including DBA/2J (Wang et al., 2005). All
107 measurements were taken approximately 10 minutes after the induction of anesthesia.
108 These IOP measurements were made on mice prior to two different experimental
109 procedures, blast injury to the eye or elevation of IOP by injection of magnetic beads into
110 the anterior chamber. When we compared the IOP of animals anesthetized with Avertin

111 to those anesthetized with ketamine/xylazine over the entire dataset there was not
112 significant difference between the two groups. We did a similar comparison looking only
113 at the C57BL/6J mice with 11 mice anesthetized with Avertin (mean IOP 10.2, SD 0.15)
114 and 27 mice anesthetized with ketamine/xylazine (mean IOP 11.2, SD 2.9) and there was
115 no statistically significant difference between the two groups using a student *t*-test.

116

117 **Interval Mapping of IOP Phenotype:** The IOP data will be subjected to conventional
118 QTL analysis using simple and composite interval mapping along with epistatic
119 interactions. Genotype was regressed against each trait using the Haley-Knott equations
120 implemented in the WebQTL module of GeneNetwork [16] [17] [18]. Empirical
121 significance thresholds of linkage are determined by permutations [19]. We correlate
122 phenotypes with expression data for whole eye and retina generated [13, 20, 21].

123

124 **Immunohistochemistry:** For immunohistochemical experiments mice were deeply
125 anesthetized with a mixture of 15 mg/kg of xylazine (AnaSed) and 100 mg/kg of
126 ketamine (Ketaset) and perfused through the heart with saline followed by 4%
127 paraformaldehyde in phosphate buffer (pH 7.3). The eye were embedded in paraffin as
128 described by Sun et al., [22]. The eyes were dehydrated in a series of ethanol and xylenes
129 changes for 20 minutes each (50% ETOH, 70% ETOH, 90% ETOH, 95% ETOH, two
130 changes of 100% ETOH, 50% ETOH with 50% xylenes, two changes of 100% xylenes,
131 two changes of paraffin. The eyes were then embedded in paraffin blocks. The eyes were
132 sectioned with a rotary microtome at 10 μ m and mounted on glass slides. The sections
133 were deparaffinized and rehydrated. The sections were rinsed in PBS, and then placed in
134 blocking buffer containing 2% donkey serum, 0.05% DMSO and 0.05% Triton X-100 for
135 30 min. The sections were rinsed in PBS, and then placed in blocking buffer containing 2%
136 donkey serum, 0.05% DMSO and 0.05% Triton X-100 for 30 min. The sections were
137 incubated in primary antibodies (1:500) against Cadherin 11 (Thermofisher, Cat. #71-
138 7600, Waltham, MA) overnight at 4°C. After rinsing, the sections were incubated with
139 secondary antibody conjugated to AlexaFluor-488 (donkey anti-rabbit, Jackson
140 Immunoresearch Cat #711-545-152, Westgrove, PA) , (1:1000), for 2 hours at room
141 temperature. The sections were then rinsed 3 times in PBS for 15 minutes each. Then

142 they were counterstained with TO-PRO-3 iodide was purchased from Invitrogen (T3605,
143 Invitrogen, Eugene OR). The slides were flooded with Fluoromount-G (SouthernBiotech
144 Cat #. 0100-01, Birmingham, AL), and covered with a coverslip. All images were
145 photographed using on Nikon Eclipse TE2000-E (Melville, NY) confocal and images
146 were acquired by Nikon's EZ-C1 Software (Bronze Version, 3.91).

147

148 **PCR Validation:** Reverse transcription-quantitative polymerase chain reaction (RT-
149 qPCR) were used to validate the mRNA expression level of Cdh11 and Cdh8 and Myoc
150 in whole eyes of C57BL/6J mice. Primers were designed for Cdh11, Cdh8 and Myoc
151 using Primer BLAST-NCBI so that predicted PCR products were approximately 150bp.
152 The cycle threshold values were normalized to a mouse housekeeping gene
153 peptidylprolyl isomerase A (Ppia). Sequences of the PCR primers are listed in
154 supplementary Table I. PCR reactions were carried out in 10 μ l reactions containing 5 μ l
155 of 2x QuantiTect SYBR Green PCR Master Mix (Qiagen, Cat #204141 Hilden,
156 Germany), 0.5 μ l of forward primer (0.5 μ M), 0.5 μ l of reverse primer (0.5 μ M), 2 μ l of
157 template cDNA(10ng) and 2 μ l of RNA free H₂O. PCR of mouse genes was performed
158 using a program beginning at 95°C for 15 min, followed by 40 cycles of reaction with
159 denaturation at 94°C for 15 sec, annealing at 59°C for 30 sec and extension at 72°C for
160 30 sec of each cycle.

161

162

163 **Results**

164 The overall goal of the present investigation was to determine if specific genomic loci
165 modulate IOP in the BXD RI strains. IOP was measured in 532 eyes form 33 BXD RI
166 strains and the two parental strains C57BL/6J mouse and DBA2/J mouse. To create a
167 mapping file the strain averages and standard errors were calculated (Figure 1). The IOP
168 measured across the 33 strains was 13.2 mmHg and the standard deviation was 1.5
169 mmHg. The strain with the lowest IOP was DBA2/J, with an average IOP of 10.9 mmHg.
170 The strain with the highest IOP was BXD48 with an average IOP of 17.1 mmHg. The
171 IOP of the parental strains was 11.6 mmHg for the C57BL/6J and 10.9 mmHg for the
172 DBA2/J. This is a substantial amount of genetic transgression across the BXD RI strain

173 set. This type of phenotypic variability is a clear indication that IOP is in fact a complex
174 trait. These data can also be used to calculate the heritability of IOP. Figure 1 reveals a
175 considerable variability in the IOP from strain to strain and the standard error for each
176 strain is rather small. This type of data suggests that the genetic variability has a greater
177 effect than the environmental variability. These data can be used to calculate the
178 heritability of IOP. To calculate heritability (H^2) is the genetic variance (V_g) of the trait is
179 divided by the sum of genetic variance plus the environmental variance ($V_g + V_e$). The
180 genetic variance can be estimated by taking the standard deviation of the mean of IOP for
181 each strain ($V_g = 1.5$ mmHg). The environmental variance can be estimated by taking the
182 mean of the standard deviation across the strain ($V_e = 3.3$ mmHg). Using the formula for
183 heritability, $H^2 = V_g / (V_g + V_e)$, the calculation of $1.5 \text{ mmHg} / (1.5 \text{ mmHg} + 3.3 \text{ mmHg})$
184 reveals that $H^2 = 0.316$. Thus, IOP is a heritability trait in the BXD RI strain set.

185

186 **Genome Wide Mapping:** Taking the average IOP from 33 strains of mice we performed
187 an unbiased genome wide scan to identify genomic loci (QTLs) that modulate IOP. The
188 genome-wide interval map (Figure 2) identifies on significant peak on Chr. 8. Examining
189 an expanded view of Chr.8, 90 to 120 Mb (Figure 3), the peak of the IOP QTL reaches
190 significance from 100 Mb to 106 Mb. BXD strains with higher IOPs (Figure 3B) tend to
191 have the C57BL/6J allele (red) and strains with lower IOPs tend to have the DBA2/J
192 allele (green). When the distribution of genes within this region is examined (gene track
193 Figure 3A) the significant portion of the QTL peak covers a region of the genome that is
194 a gene desert. Within this region there are only 5 genes: *Arl5a* (ADP-ribosylation factor-
195 like 5a), *Cdh11* (cadherin11), *Cdh8* (cadherin 8), *Gm15679* (predicted gene 15679) and
196 *Rplp0* (ribosomal protein, large, P0). Using the tools available on GeneNetwork
197 (genenetwork.org) we are able to identify potential candidates for modulating IOP in the
198 BXD RI strains. The candidate genes can either be genomic elements with cis-QTLs or
199 they can be genes with nonsynonymous SNPs changing protein sequence. Within this
200 region there are only two putative candidate genes. There are cisQTL for *Cdh11*(exon
201 probes 17512155 and 17512156, build 2016-12-12 GeneNetwork). There are two genes
202 in this region with non-synonymous SNPs, *Cdh11* and *Cdh8*. Thus, there is a single QTL

203 modulating IOP and this peak lies in a gene desert with only two good candidate genes
204 *Cdh11* and *Cdh8*.

205

206 For the initial evaluation of the two candidate genes we examined their expression level
207 in microarray datasets hosted on GeneNetwork: the eye database (Eye M430v2 (Sep08)
208 RMA) and retina database (DoD Retina Normal Affy MoGene 2.0 ST (May15) RMA
209 Gene Level). In the eye dataset, the highest level of expression for a *Cdh11* probe set
210 (1450757_at) is 10.8 Log₂, while for *Cdh8* (1422052_at) the highest level of expression
211 is 7.3 Log₂. For this dataset the mean expression of mRNA in the retina is set to 8. Thus,
212 *Cdh11* is expressed at levels higher than the mean and *Cdh8* is expressed at levels below
213 the average expression level. Furthermore, in the whole eye database, there is over an 8-
214 fold increase in expression of *Cdh11* relative to *Cdh8*. In the retina database, *Cdh11*
215 (probe set 17512153) had an expression level of 10.9 and *Cdh8* (probe set 17512121) had
216 an expression level of 9.3, indicating that within the retina proper *Cdh11* expression is
217 2-fold higher than *Cdh8*.

218

219 To confirm the expression levels of *Cdh11* and *Cdh8* in the eye, we examined the levels
220 of mRNA in the whole eye by RT-qPCR. In 4 biological replicate RNA samples, we
221 examined the levels of *Cdh11*, *Cdh8* and *Myoc* (a marker of trabecular meshwork cells,
222 [23]). Our PCR analysis confirmed the general findings of the microarray data sets. In
223 the 4 biological samples of whole eye, *Cdh11* was more highly expressed than *Cdh8*. The
224 average of the 4 samples demonstrated a more than 2-fold higher expression of *Cdh11*
225 than *Cdh8*. *Myoc* was also expressed at a higher level than *Cdh8* but at approximately at
226 the same level as *Cdh11*. All of these data taken together indicate that *Cdh11* is the prime
227 candidate for an upstream modulator of IOP.

228

229 **Distribution of Cadherin 11 in the Eye:** To determine if cadherin 11 is found in
230 structures associated with the control of IOP, we stained sections of the eye for cadherin
231 11. In these sections, there was a considerable amount of antibody-specific staining (Fig.
232 4A). This label is not observed in control sections stained with secondary antibody only
233 (Fig. 4B). There is extensive labeling of all layers of the cornea. The epithelium of the

234 ciliary body is also heavily labeled as well as labeling of pars plana. There is also light
235 labeling of the retina. At higher magnification (Fig. 4C), clear labeling of the trabecular
236 meshwork (arrow). Thus, cadherin 11 is expressed in the cells of the trabecular
237 meshwork, the primary structure involved in regulating IOP.

238

239

240 **Discussion**

241 The normal regulation of intraocular pressure is a balance between production in the
242 ciliary body and outflow [24, 25]. In the human, IOP ranges can range from a relatively
243 low pressures to extremely high that occur in acute angle closure glaucoma. It is
244 generally accepted that the “normal” range for IOP in humans is from 12mmHg to
245 22mmHg [26, 27]. In addition, monitoring throughout the day reveals IOP is pulsatory
246 and has a diurnal variability [28]. These findings tell an interesting story about the
247 regulation of pressure in the eye; however, the primary driving force behind the intense
248 investigation of IOP in humans is that fact that it is the primary risk factor for developing
249 glaucoma [29]. Furthermore, all of the current treatments for glaucoma center around
250 lowering IOP either by pharmacological approaches or surgery [30, 31].

251

252 The association of elevated IOP and glaucoma, has driven most of the study of IOP in
253 human populations [5, 32, 33]. Most of these studies involve the study of glaucoma, but
254 a few have a primary focus on the regulation of IOP. These studies have found that
255 IOP is a heritable trait with estimates of heritability ranging from 0.39 to 0.64 [6, 34-36].
256 In the present study, we found that the heritability of IOP in the BXD RI strains was 0.36.
257 Thus, the mouse strains demonstrated a heritability near the lower end of the human
258 populations. The interest has prompted studies to identify genes regulating IOP. In a
259 genome-wide association study of IOP involving 11,972 subjects, significant associations
260 were observed with SNPs in two genes, *GAS7* and *TMCO1* [37]. Both of these genes are
261 expressed at high levels in the ciliary body and trabecular meshwork [38] and both of the
262 genes interact with known glaucoma risk genes [37]. *TMCO1* is also known to be
263 associated with severe glaucoma risk [39].

264

265 In an effort to understand the regulation of IOP and its effects on the retina, many
266 research groups have used inbred mouse strains [40-44]. IOP varies widely across
267 different strains of mice [40, 45], ranging from a low of 11mmHg in the BALB/c mouse
268 strain to a high of 19mmHg in the CBA/Ca mouse strain. In the present study, the
269 average measured IOP across the 33 strains was 13.2mmHg. The lowest measured IOP
270 was 10.9mmHg in the DBA/2J strain and the highest was 17.1mmHg in the BXD48
271 strain. Using the variability across the BXD RI strains we were able to map a single
272 significant QTL on Chr. 8 in the mouse. The peak of the QTL was in a gene desert and
273 within this region there were only two potential candidate genes that could be modulating
274 IOP in the BXD strain set. Based on expression of mRNA in the eye microarray dataset
275 and the findings of real time PCR *Cdh11* appears to be the best candidate. *Cdh11* is
276 expressed approximately 8-fold higher in the eye than is *Cdh8*. Furthermore, previous
277 study [46] found *CDH11* to be highly expressed in cultured human trabecular meshwork
278 cells. We found that Cadherin 11 is expressed in the trabecular meshwork using indirect
279 immunohistochemistry. All of these data suggest that the expression Cadherin 11 in the
280 trabecular meshwork modulates IOP across the BXD RI strain set.

281

282 How is it possible that a cadherin can modulate IOP in the mouse eye? IOP is regulated
283 by fluid resistance at the trabecular meshwork and Schlemm's canal [47, 48]. The
284 stiffness of these structures is determined by the extracellular matrix within the trabecular
285 meshwork and Schlemm's canal and the contractile nature of the cells themselves (Zhou
286 et al. 2012) inner wall was considered to be the most important player regulating such
287 resistance [49-51]. The dysregulation or poor organization of extracellular matrix may
288 increase the fluid resistance, leading to an elevation of the IOP. *Cdh11* was recently
289 revealed to be a novel regulator of extracellular matrix synthesis and tissue
290 mechanics[52] , and it is also found to be highly expressed in cultured human trabecular
291 meshwork cells [46]. It is possible that the IOP can be regulated by *Cdh11* and related
292 pathways by altering the extracellular matrix structure of the trabecular meshwork. Future
293 studies about the role of *Cdh11* in the trabecular meshwork may give insights into the
294 mechanism of IOP modulation.

295

296

297

298

299 Acknowledgements: We would like to thank the Robert W Williams and his group for
300 providing a wealth of bioinformatic resources on GeneNetwork.org. We thank Chelsey
301 Faircloth for her assistance in immunostaining. This study was supported by an
302 Unrestricted Grand from Research to Prevent Blindness, NEI grant R01EY017841
303 (E.E.G.), Owens Family Glaucoma Research Fund, P30EY06360 (Emory Vision Core)
304 and DoD CDMRP Grant W81XWH-12-1-0255 from the USA Army Medical Research &
305 Materiel Command and the Telemedicine and Advanced Technology (E.E.G.).

306

307

308

309 **References**

310


- 311 1. European Glaucoma Prevention Study G, Miglior S, Pfeiffer N, Torri V,
312 Zeyen T, Cunha-Vaz J, Adamsons I. Predictive factors for open-angle glaucoma
313 among patients with ocular hypertension in the European Glaucoma Prevention
314 Study. *Ophthalmology* 2007; 114(1):3-9.
- 315 2. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z, Group E.
316 Predictors of long-term progression in the early manifest glaucoma trial.
317 *Ophthalmology* 2007; 114(11):1965-72.
- 318 3. Medeiros FA, Sample PA, Zangwill LM, Bowd C, Aihara M, Weinreb RN.
319 Corneal thickness as a risk factor for visual field loss in patients with
320 preperimetric glaucomatous optic neuropathy. *Am J Ophthalmol* 2003;
321 136(5):805-13.
- 322 4. Herndon LW, Weizer JS, Stinnett SS. Central corneal thickness as a risk
323 factor for advanced glaucoma damage. *Arch Ophthalmol* 2004; 122(1):17-21.
- 324 5. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson
325 CA, Keltner JL, Miller JP, Parrish RK, 2nd, Wilson MR, Kass MA. The Ocular
326 Hypertension Treatment Study: baseline factors that predict the onset of primary
327 open-angle glaucoma. *Arch Ophthalmol* 2002; 120(6):714-20; discussion 829-30.
- 328 6. Klein BE, Klein R, Lee KE. Heritability of risk factors for primary open-
329 angle glaucoma: the Beaver Dam Eye Study. *Invest Ophthalmol Vis Sci* 2004;
330 45(1):59-62.
- 331 7. Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR, Sunden SL,
332 Nishimura D, Clark AF, Nystuen A, Nichols BE, Mackey DA, Ritch R, Kalenak
333 JW, Craven ER, Sheffield VC. Identification of a gene that causes primary open
334 angle glaucoma. *Science* 1997; 275(5300):668-70.
- 335 8. Wiggs JL. Genetic etiologies of glaucoma. *Arch Ophthalmol* 2007;
336 125(1):30-7.
- 337 9. Joe MK, Sohn S, Hur W, Moon Y, Choi YR, Kee C. Accumulation of
338 mutant myocilins in ER leads to ER stress and potential cytotoxicity in human
339 trabecular meshwork cells. *Biochem Biophys Res Commun* 2003; 312(3):592-
340 600.
- 341 10. Kasetti RB, Phan TN, Millar JC, Zode GS. Expression of Mutant Myocilin
342 Induces Abnormal Intracellular Accumulation of Selected Extracellular Matrix
343 Proteins in the Trabecular Meshwork. *Invest Ophthalmol Vis Sci* 2016;
344 57(14):6058-69.
- 345 11. Peirce JL, Lu L, Gu J, Silver LM, Williams RW. A new set of BXD
346 recombinant inbred lines from advanced intercross populations in mice. *BMC*
347 *Genet* 2004; 5:7.
- 348 12. Mozhui K, Ciobanu DC, Schikorski T, Wang X, Lu L, Williams RW.
349 Dissection of a QTL hotspot on mouse distal chromosome 1 that modulates
350 neurobehavioral phenotypes and gene expression. *PLoS Genet* 2008;
351 4(11):e1000260.

- 352 13. Geisert EE, Lu L, Freeman-Anderson NE, Templeton JP, Nassr M, Wang
353 X, Gu W, Jiao Y, Williams RW. Gene expression in the mouse eye: an online
354 resource for genetics using 103 strains of mice. *Mol Vis* 2009; 15:1730-63.
- 355 14. Freeman NE, Templeton JP, Orr WE, Lu L, Williams RW, Geisert EE.
356 Genetic networks in the mouse retina: growth associated protein 43 and
357 phosphatase tensin homolog network. *Mol Vis* 2011; 17:1355-72.
- 358 15. Anderson MG, Smith RS, Hawes NL, Zabaleta A, Chang B, Wiggs JL,
359 John SW. Mutations in genes encoding melanosomal proteins cause pigmentary
360 glaucoma in DBA/2J mice. *Nat Genet* 2002; 30(1):81-5.
- 361 16. Chesler EJ, Lu L, Shou S, Qu Y, Gu J, Wang J, Hsu HC, Mountz JD,
362 Baldwin NE, Langston MA, Threadgill DW, Manly KF, Williams RW. Complex trait
363 analysis of gene expression uncovers polygenic and pleiotropic networks that
364 modulate nervous system function. *Nat Genet* 2005; 37(3):233-42.
- 365 17. Rosen GD, La Porte NT, Diechtiareff B, Pung CJ, Nissanov J, Gustafson
366 C, Bertrand L, Gefen S, Fan Y, Tretiak OJ, Manly KF, Park MR, Williams AG,
367 Connolly MT, Capra JA, Williams RW. Informatics center for mouse genomics:
368 the dissection of complex traits of the nervous system. *Neuroinformatics* 2003;
369 1(4):327-42.
- 370 18. Carlborg O, De Koning DJ, Manly KF, Chesler E, Williams RW, Haley CS.
371 Methodological aspects of the genetic dissection of gene expression.
372 *Bioinformatics* 2005; 21(10):2383-93.
- 373 19. Churchill GA, Doerge RW. Empirical threshold values for quantitative trait
374 mapping. *Genetics* 1994; 138(3):963-71.
- 375 20. King R, Lu L, Williams RW, Geisert EE. Transcriptome networks in the
376 mouse retina: An exon level BXD RI database. *Mol Vis* 2015; 21:1235-51.
- 377 21. Templeton JP, Freeman NE, Nickerson JM, Jablonski MM, Rex TS,
378 Williams RW, Geisert EE. Innate immune network in the retina activated by optic
379 nerve crush. *Invest Ophthalmol Vis Sci* 2013; 54(4):2599-606.
- 380 22. Sun N, Shibata B, Hess JF, FitzGerald PG. An alternative means of
381 retaining ocular structure and improving immunoreactivity for light microscopy
382 studies. *Mol Vis* 2015; 21:428-42.
- 383 23. Takahashi H, Noda S, Imamura Y, Nagasawa A, Kubota R, Mashima Y,
384 Kudoh J, Oguchi Y, Shimizu N. Mouse myocilin (Myoc) gene expression in ocular
385 tissues. *Biochem Biophys Res Commun* 1998; 248(1):104-9.
- 386 24. Brubaker RF. Flow of Aqueous-Humor in Humans - the Friedenwald
387 Lecture. *Invest Ophth Vis Sci* 1991; 32(13):3145-66.
- 388 25. Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor
389 dynamics: a review. *Open Ophthalmol J* 2010; 4:52-9.
- 390 26. Hollows FC, Graham PA. Intra-ocular pressure, glaucoma, and glaucoma
391 suspects in a defined population. *Br J Ophthalmol* 1966; 50(10):570-86.
- 392 27. Renard E, Palombi K, Gronfier C, Pepin JL, Noel C, Chiquet C, Romanet
393 JP. Twenty-four hour (Nyctohemeral) rhythm of intraocular pressure and ocular
394 perfusion pressure in normal-tension glaucoma. *Invest Ophthalmol Vis Sci* 2010;
395 51(2):882-9.

- 396 28. Aptel F, Weinreb RN, Chiquet C, Mansouri K. 24-h monitoring devices and
397 nyctohemeral rhythms of intraocular pressure. *Prog Retin Eye Res* 2016; 55:108-
398 48.
- 399 29. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt J, Singh K.
400 Relationship between intraocular pressure and primary open angle glaucoma
401 among white and black Americans. The Baltimore Eye Survey. *Arch Ophthalmol*
402 1991; 109(8):1090-5.
- 403 30. Cohen LP, Pasquale LR. Clinical characteristics and current treatment of
404 glaucoma. *Cold Spring Harb Perspect Med* 2014; 4(6).
- 405 31. Gedde SJ, Panarelli JF, Banitt MR, Lee RK. Evidenced-based comparison
406 of aqueous shunts. *Curr Opin Ophthalmol* 2013; 24(2):87-95.
- 407 32. Ojha P, Wiggs JL, Pasquale LR. The genetics of intraocular pressure.
408 *Semin Ophthalmol* 2013; 28(5-6):301-5.
- 409 33. Ozel AB, Moroi SE, Reed DM, Nika M, Schmidt CM, Akbari S, Scott K,
410 Rozsa F, Pawar H, Musch DC, Lichter PR, Gaasterland D, Branham K, Gilbert J,
411 Garnai SJ, Chen W, Othman M, Heckenlively J, Swaroop A, Abecasis G,
412 Friedman DS, Zack D, Ashley-Koch A, Ulmer M, Kang JH, Consortium N, Liu Y,
413 Yaspan BL, Haines J, Allingham RR, Hauser MA, Pasquale L, Wiggs J, Richards
414 JE, Li JZ. Genome-wide association study and meta-analysis of intraocular
415 pressure. *Hum Genet* 2014; 133(1):41-57.
- 416 34. Chang TC, Congdon NG, Wojciechowski R, Munoz B, Gilbert D, Chen P,
417 Friedman DS, West SK. Determinants and heritability of intraocular pressure and
418 cup-to-disc ratio in a defined older population. *Ophthalmology* 2005;
419 112(7):1186-91.
- 420 35. Carbonaro F, Andrew T, Mackey DA, Young TL, Spector TD, Hammond
421 CJ. Repeated measures of intraocular pressure result in higher heritability and
422 greater power in genetic linkage studies. *Invest Ophthalmol Vis Sci* 2009;
423 50(11):5115-9.
- 424 36. van Koolwijk LM, Despriet DD, van Duijn CM, Pardo Cortes LM, Vingerling
425 JR, Aulchenko YS, Oostra BA, Klaver CC, Lemij HG. Genetic contributions to
426 glaucoma: heritability of intraocular pressure, retinal nerve fiber layer thickness,
427 and optic disc morphology. *Invest Ophthalmol Vis Sci* 2007; 48(8):3669-76.
- 428 37. van Koolwijk LM, Ramdas WD, Ikram MK, Jansonius NM, Pasutto F, Hysi
429 PG, Macgregor S, Janssen SF, Hewitt AW, Viswanathan AC, ten Brink JB,
430 Hosseini SM, Amin N, Despriet DD, Willemse-Assink JJ, Kramer R, Rivadeneira
431 F, Struchalin M, Aulchenko YS, Weisschuh N, Zenkel M, Mardin CY, Gramer E,
432 Welge-Lussen U, Montgomery GW, Carbonaro F, Young TL, Group DER,
433 Bellenguez C, McGuffin P, Foster PJ, Topouzis F, Mitchell P, Wang JJ, Wong
434 TY, Czudowska MA, Hofman A, Uitterlinden AG, Wolfs RC, de Jong PT, Oostra
435 BA, Paterson AD, Wellcome Trust Case Control C, Mackey DA, Bergen AA, Reis
436 A, Hammond CJ, Vingerling JR, Lemij HG, Klaver CC, van Duijn CM. Common
437 genetic determinants of intraocular pressure and primary open-angle glaucoma.
438 *PLoS Genet* 2012; 8(5):e1002611.
- 439 38. Liton PB, Luna C, Challa P, Epstein DL, Gonzalez P. Genome-wide
440 expression profile of human trabecular meshwork cultured cells,


- 441 nonglaucomatous and primary open angle glaucoma tissue. *Mol Vis* 2006;
442 12:774-90.
- 443 39. Burdon KP, Macgregor S, Hewitt AW, Sharma S, Chidlow G, Mills RA,
444 Danoy P, Casson R, Viswanathan AC, Liu JZ, Landers J, Henders AK, Wood J,
445 Souzeau E, Crawford A, Leo P, Wang JJ, Rochtchina E, Nyholt DR, Martin NG,
446 Montgomery GW, Mitchell P, Brown MA, Mackey DA, Craig JE. Genome-wide
447 association study identifies susceptibility loci for open angle glaucoma at TMCO1
448 and CDKN2B-AS1. *Nat Genet* 2011; 43(6):574-8.
- 449 40. Savinova OV, Sugiyama F, Martin JE, Tomarev SI, Paigen BJ, Smith RS,
450 John SW. Intraocular pressure in genetically distinct mice: an update and strain
451 survey. *BMC Genet* 2001; 2:12.
- 452 41. Struebing FL, Geisert EE. What Animal Models Can Tell Us About
453 Glaucoma. *Prog Mol Biol Transl Sci* 2015; 134:365-80.
- 454 42. Sappington RM, Carlson BJ, Crish SD, Calkins DJ. The microbead
455 occlusion model: a paradigm for induced ocular hypertension in rats and mice.
456 *Invest Ophthalmol Vis Sci* 2010; 51(1):207-16.
- 457 43. Cone FE, Gelman SE, Son JL, Pease ME, Quigley HA. Differential
458 susceptibility to experimental glaucoma among 3 mouse strains using bead and
459 viscoelastic injection. *Exp Eye Res* 2010; 91(3):415-24.
- 460 44. Samsel PA, Kisiswa L, Erichsen JT, Cross SD, Morgan JE. A novel
461 method for the induction of experimental glaucoma using magnetic
462 microspheres. *Invest Ophthalmol Vis Sci* 2011; 52(3):1671-5.
- 463 45. Wang WH, Millar JC, Pang IH, Wax MB, Clark AF. Noninvasive
464 measurement of rodent intraocular pressure with a rebound tonometer. *Invest*
465 *Ophthalmol Vis Sci* 2005; 46(12):4617-21.
- 466 46. Paylakhi SH, Yazdani S, April C, Fan JB, Moazzeni H, Ronaghi M, Elahi
467 E. Non-housekeeping genes expressed in human trabecular meshwork cell
468 cultures. *Mol Vis* 2012; 18:241-54.
- 469 47. Ethier CR, Kamm RD, Palaszewski BA, Johnson MC, Richardson TM.
470 Calculations of flow resistance in the juxtacanalicular meshwork. *Invest*
471 *Ophthalmol Vis Sci* 1986; 27(12):1741-50.
- 472 48. Brubaker RF. The effect of intraocular pressure on conventional outflow
473 resistance in the enucleated human eye. *Invest Ophthalmol* 1975; 14(4):286-92.
- 474 49. Bradley JM, Vranka J, Colvis CM, Conger DM, Alexander JP, Fisk AS,
475 Samples JR, Acott TS. Effect of matrix metalloproteinases activity on outflow in
476 perfused human organ culture. *Invest Ophthalmol Vis Sci* 1998; 39(13):2649-58.
- 477 50. Johnson M. 'What controls aqueous humour outflow resistance?'. *Exp Eye*
478 *Res* 2006; 82(4):545-57.
- 479 51. Vranka JA, Kelley MJ, Acott TS, Keller KE. Extracellular matrix in the
480 trabecular meshwork: intraocular pressure regulation and dysregulation in
481 glaucoma. *Exp Eye Res* 2015; 133:112-25.
- 482 52. Row S, Liu Y, Alimperti S, Agarwal SK, Andreadis ST. Cadherin-11 is a
483 novel regulator of extracellular matrix synthesis and tissue mechanics. *J Cell Sci*
484 2016; 129(15):2950-61.
- 485

486 **Figures**
487
488



489
490
491 **Figure 1.** The distribution of IOP measurements across the BXD strains is illustrated in a
492 bar chart with means and Standard Deviations. In the 33 strains of mice the IOP ranged
493 from a low of 10.9 mmHg to a high of 17.1 mmHg.

494
495
496
497
498
499
500
501
502
503
504
505
506
507




508
509

510 **Figure 2.** A genome-wide interval map of IOP. The interval map plots the linkage
511 related score (LRS) across the genome from chromosome 1 to chromosome X. The light
512 gray line is the suggestive level and the light red line is genome-wide significance ($p =$
513 0.05). When the IOP measures were mapped to the mouse genome there was a significant
514 association between IOP and a locus on Chromosome 8.


515

516
517



518
519
520
521
522
523
524
525
526
527
528
529
530
531

Figure 3. The interval map for Chr. 8: 90 to 120Mb is illustrated. A is the gene tract, that identifies the locations of known genes across the genome. B is a haplotype map for the different BXD RI strains listed to the right and ranked from the highest IOP to the lowest IOP. The location of genomic markers is indicated by black vertical lines. C is an expanded version of the interval map for IOP. Finally, the bottom trace (yellow) identified the location of SNPs between the C57BL/6 mouse and the DBA2/J mouse. The genomic location is indicated along this lower trace. Notice that the peak of the QTL in C sits in a region of the genome that contains very few known genes (A).



532

533

534

535 **Figure 4.** The distribution of cadherin 11 in the limbal area of the eye is illustrated. The

536 section in A was stained with an antibody specific to cadherin 11 (green) and for DNA

537 (blue). This staining is specific to the primary antibody for it is not observed in a section

538 stained with the secondary antibody alone (B). The staining pattern of the trabecular

539 meshwork is shown at higher magnification in C (arrow). A and B are taken at the same

540 magnification and the scale bar in panel B represents 25 μm .

541

542

543

544

545


546 **Table 1.** Primers designed for Cdh11 and Cdh8 and Myoc

547

Cdh11	Forward 5' GAAACCAAAGTCCCAGTGGCC 3'
	Reverse 5' TGGTCCATTGGCTGTGTCGT 3'
Cdh8	Forward 5' AGCCTCCGGTCTTCTCTTCAC 3'
	Reverse 5' CAGTGTGGCGGTCAATGGAAA 3'
Myoc	Forward 5' GCTGGCTACCACGGACACTT 3'
	Reverse 5' CGCTCAAGTTCCAGGTTTCGC 3'
Ppia	Mm_Ppia_1_SG QuantiTect Primer Assay

548

mmHg



— LD
— Positive Effect
— Negative LD = 10.00
— Negative LD = 14.00

Task 20: Tmp - Chr_TSP_201401
Mapping for Dataset: 2014, mapping on All Chromosomes
Using R package: mapping function with no control for other QTLs
Using GeneMap file: New_GeneMap (2014)

